Literature DB >> 19591830

Bone morphogenetic protein signaling is impaired in an HFE knockout mouse model of hemochromatosis.

Elena Corradini1, Cinzia Garuti, Giuliana Montosi, Paolo Ventura, Billy Andriopoulos, Herbert Y Lin, Antonello Pietrangelo, Jodie L Babitt.   

Abstract

BACKGROUND AND AIMS: Mutations in HFE are the most common cause of the iron-overload disorder hereditary hemochromatosis. Levels of the main iron regulatory hormone, hepcidin, are inappropriately low in hereditary hemochromatosis mouse models and patients with HFE mutations, indicating that HFE regulates hepcidin. The bone morphogenetic protein 6 (BMP6)-SMAD signaling pathway is an important endogenous regulator of hepcidin expression. We investigated whether HFE is involved in BMP6-SMAD regulation of hepcidin expression.
METHODS: The BMP6-SMAD pathway was examined in Hfe knockout (KO) mice and in wild-type (WT) mice as controls. Mice were placed on diets of varying iron content. Hepcidin induction by BMP6 was examined in primary hepatocytes from Hfe KO mice; data were compared with those of WT mice.
RESULTS: Liver levels of Bmp6 messenger RNA (mRNA) were higher in Hfe KO mice; these were appropriate for the increased hepatic levels of iron in these mice, compared with WT mice. However, levels of hepatic phosphorylated Smad 1/5/8 protein (an intracellular mediator of Bmp6 signaling) and Id1 mRNA (a target gene of Bmp6) were inappropriately low for the body iron burden and Bmp6 mRNA levels in Hfe KO, compared with WT mice. BMP6 induction of hepcidin expression was reduced in Hfe KO hepatocytes compared with WT hepatocytes.
CONCLUSIONS: HFE is not involved in regulation of BMP6 by iron, but does regulate the downstream signals of BMP6 that are triggered by iron.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19591830      PMCID: PMC2757523          DOI: 10.1053/j.gastro.2009.06.057

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  48 in total

1.  Global prevalence of putative haemochromatosis mutations.

Authors:  A T Merryweather-Clarke; J J Pointon; J D Shearman; K J Robson
Journal:  J Med Genet       Date:  1997-04       Impact factor: 6.318

Review 2.  Mechanisms of TGF-beta signaling from cell membrane to the nucleus.

Authors:  Yigong Shi; Joan Massagué
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

3.  A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis.

Authors:  J N Feder; A Gnirke; W Thomas; Z Tsuchihashi; D A Ruddy; A Basava; F Dormishian; R Domingo; M C Ellis; A Fullan; L M Hinton; N L Jones; B E Kimmel; G S Kronmal; P Lauer; V K Lee; D B Loeb; F A Mapa; E McClelland; N C Meyer; G A Mintier; N Moeller; T Moore; E Morikang; C E Prass; L Quintana; S M Starnes; R C Schatzman; K J Brunke; D T Drayna; N J Risch; B R Bacon; R K Wolff
Journal:  Nat Genet       Date:  1996-08       Impact factor: 38.330

4.  The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression.

Authors:  J N Feder; Z Tsuchihashi; A Irrinki; V K Lee; F A Mapa; E Morikang; C E Prass; S M Starnes; R K Wolff; S Parkkila; W S Sly; R C Schatzman
Journal:  J Biol Chem       Date:  1997-05-30       Impact factor: 5.157

5.  Regulatory defects in liver and intestine implicate abnormal hepcidin and Cybrd1 expression in mouse hemochromatosis.

Authors:  Martina Muckenthaler; Cindy N Roy; Angel O Custodio; Belén Miñana; Jos deGraaf; Lynne K Montross; Nancy C Andrews; Matthias W Hentze
Journal:  Nat Genet       Date:  2003-05       Impact factor: 38.330

6.  Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis.

Authors:  Gaël Nicolas; Lydie Viatte; Dan-Qing Lou; Myriam Bennoun; Carole Beaumont; Axel Kahn; Nancy C Andrews; Sophie Vaulont
Journal:  Nat Genet       Date:  2003-05       Impact factor: 38.330

7.  HFE and transferrin directly compete for transferrin receptor in solution and at the cell surface.

Authors:  Anthony M Giannetti; Pamela J Björkman
Journal:  J Biol Chem       Date:  2004-03-31       Impact factor: 5.157

8.  Decreased liver hepcidin expression in the Hfe knockout mouse.

Authors:  Kaashif A Ahmad; John R Ahmann; Mary C Migas; Abdul Waheed; Robert S Britton; Bruce R Bacon; William S Sly; Robert E Fleming
Journal:  Blood Cells Mol Dis       Date:  2002 Nov-Dec       Impact factor: 3.039

9.  Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis.

Authors:  George Papanikolaou; Mark E Samuels; Erwin H Ludwig; Marcia L E MacDonald; Patrick L Franchini; Marie-Pierre Dubé; Lisa Andres; Julie MacFarlane; Nikos Sakellaropoulos; Marianna Politou; Elizabeta Nemeth; Jay Thompson; Jenni K Risler; Catherine Zaborowska; Ryan Babakaiff; Christopher C Radomski; Terry D Pape; Owen Davidas; John Christakis; Pierre Brissot; Gillian Lockitch; Tomas Ganz; Michael R Hayden; Y Paul Goldberg
Journal:  Nat Genet       Date:  2003-11-30       Impact factor: 38.330

Review 10.  Hereditary hemochromatosis--a new look at an old disease.

Authors:  Antonello Pietrangelo
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

View more
  60 in total

Review 1.  Unraveling mechanisms regulating systemic iron homeostasis.

Authors:  Karin E Finberg
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

Review 2.  Murine mutants in the study of systemic iron metabolism and its disorders: an update on recent advances.

Authors:  Thomas B Bartnikas; Mark D Fleming; Paul J Schmidt
Journal:  Biochim Biophys Acta       Date:  2012-01-28

Review 3.  Liver iron sensing and body iron homeostasis.

Authors:  Chia-Yu Wang; Jodie L Babitt
Journal:  Blood       Date:  2018-11-06       Impact factor: 22.113

Review 4.  The liver: conductor of systemic iron balance.

Authors:  Delphine Meynard; Jodie L Babitt; Herbert Y Lin
Journal:  Blood       Date:  2013-11-07       Impact factor: 22.113

5.  The bone morphogenetic protein-hepcidin axis as a therapeutic target in inflammatory bowel disease.

Authors:  Lijian Wang; Estela Trebicka; Ying Fu; Shiri Ellenbogen; Charles C Hong; Jodie L Babitt; Herbert Y Lin; Bobby J Cherayil
Journal:  Inflamm Bowel Dis       Date:  2011-02-23       Impact factor: 5.325

6.  Combinatorial use of bone morphogenetic protein 6, noggin and SOST significantly predicts cancer progression.

Authors:  Hiu-Fung Yuen; Cian M McCrudden; Claire Grills; Shu-Dong Zhang; Yu-Han Huang; Ka-Kui Chan; Yuen-Piu Chan; Michelle Lok-Yee Wong; Simon Law; Gopesh Srivastava; Dean A Fennell; Glenn Dickson; Mohamed El-Tanani; Kwok-Wah Chan
Journal:  Cancer Sci       Date:  2012-04-03       Impact factor: 6.716

7.  Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats.

Authors:  Igor Theurl; Andrea Schroll; Thomas Sonnweber; Manfred Nairz; Milan Theurl; Wolfgang Willenbacher; Kathrin Eller; Dominik Wolf; Markus Seifert; Chia Chi Sun; Jodie L Babitt; Charles C Hong; Tracey Menhall; Patrick Gearing; Herbert Y Lin; Guenter Weiss
Journal:  Blood       Date:  2011-07-05       Impact factor: 22.113

Review 8.  Iron and inflammation - the gut reaction.

Authors:  Smriti Verma; Bobby J Cherayil
Journal:  Metallomics       Date:  2017-02-22       Impact factor: 4.526

Review 9.  Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches.

Authors:  Paul J Schmidt; Mark D Fleming
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

10.  Therapeutic effects of induced pluripotent stem cells in chimeric mice with β-thalassemia.

Authors:  Guanheng Yang; Wansheng Shi; Xingyin Hu; Jingzhi Zhang; Zhijuan Gong; Xinbing Guo; Zhaorui Ren; Fanyi Zeng
Journal:  Haematologica       Date:  2014-05-09       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.